Objective

To exam the association between major psychiatry illness and angiotensin-converting enzyme inhibitor (ACEI) versus angiotensin receptor blocker (ARB) users in a head-to-head comparison manner.

Methods

Study design is a retrospective cohort study utilizing available data through the National Health Insurance database. 13,974 ACEI users and 13,974 propensity score matching ARB users were included to look at the future incident psychiatry illness. The Kaplan-Meier method was used to assess the cumulative curves and were tested by the Log-rank test. The crude hazard ratio (HR) and adjusted HR were estimated by univariable and multivariable Cox proportional hazard model.

Results

After controlling for the confounders, ACEI users had a higher risk of major psychiatric disorders than ARB users, (adjusted HR = 1.07; 95% CI = 1.02, 1.13). The cumulative incidence of major psychiatric disorders for ACEI cohort was significantly higher than that of ARB cohort (p-value = 0.001).

Conclusions

Compared to ARB users, ACEI users are prone to major psychiatry illness development.

中文翻译：

---

血管紧张素转换酶抑制剂，血管紧张素受体阻滞剂与主要精神疾病之间的关联

客观的

以头对头比较的方式检查主要精神病患者与血管紧张素转换酶抑制剂（ACEI）与血管紧张素受体阻滞剂（ARB）使用者之间的关联。

方法

研究设计是一项回顾性队列研究，利用国家健康保险数据库中的可用数据。包括13974名ACEI用户和13974名倾向得分匹配的ARB用户，以观察未来发生的精神病疾病。Kaplan-Meier方法用于评估累积曲线，并通过对数秩检验进行检验。通过单变量和多变量Cox比例风险模型估算粗风险比（HR）和调整后的HR。

结果

在控制了混杂因素之后，ACEI使用者比ARB使用者具有更大的精神疾病风险（调整后的HR = 1.07； 95％CI = 1.02，1.13）。ACEI队列的主要精神疾病累积发生率显着高于ARB队列（p值= 0.001）。

结论

与ARB用户相比，ACEI用户容易出现重大精神疾病。